Abstract: The invention relates to new quinoline derivatives of the formula: ##STR1## wherein R stands for C.sub.2 H.sub.5, C.sub.2 H.sub.4 F, CH.sub.2 -O-CH.sub.2 -CH.sub.2 OH, ##STR2## to a process for their preparation comprising reacting, for 12-24 hours, at 70.degree.-95.degree. C., in dimethylformamide, the 1,4-dihydro- 3-ethoxycarbonyl- 6,8- difluoro-4-oxo-quinoline with an excess of RX (2-5 mol of RX for one mol of quinoline), in the presence of K.sub.2 CO.sub.3 and subsequently hydrolysing the obtained 3-ester by HCl under reflux conditions and to pharmaceutical compositions comprising at least one 1,4-dihydro- 3-carboxy- 6,8-difluoro- 1-R-4-oxo-quinoline derivative in admixture with a pharmaceutically acceptable diluent or carrier.

Abstract: The present invention relates to an ophthalmological composition of matter comprising a suspension of eicosapentaenoic acid in an alkyl cellulose and/or hydroxyalkyl aqueous cellulose solution to be used in any case of ocular inflammation on men and/or on aminals.The invention also relates to the use of said eicosapentaenoic acid and to a method for the treatment of ocular inflammation by the same.

Abstract: This invention relates to:(a) new tetrahydrofuran derivatives having the general formula I: ##STR1## wherein either each of R and R' independently represents a hydrogen atom or various hydrocarbon substituents and A represents either a nitrogen containing ring or an alkylammonium salt or an alkylaminoacid rest;(b) a process for the preparation of said compounds and(c) therapeutic compositions containing said compounds as an active ingredient.

Abstract: This invention relates to new tetrahydrofurans and tetrahydrothiophenes of the general formula: ##STR1## wherein X stands for O or S, m is an integer from 1 to 12 and A is a pyridinium or an ammonium salt, to a preparation process of said compounds and to therapeutic compositions of matter containing the same.

Abstract: This invention relates to modified clays comprising a sheet-silicate clay with a plate separation of from 1.5 to 1.6 nm, with a neutralizing power of from 170 to 1200 mEq per 100 g combined with 0.05 to 0.5 part in weight of magnesium hydroxide per part of clay, and acidic addition products of the same. The invention relates also to a preparation process of these clays, consisting in treating at a temperature between 50.degree. C. and about 140.degree. C., possibly under pressure, one part of an appropriate sheet-silicate clay by 0.05 to 0.5 part of magnesium hydroxide for about 3 hours to about 24 hours. The invention relates finally to therapeutic composition of matter comprising as an essential ingredient therein, a sufficient amount of these modified clays.

Abstract: The invention relates to new quinoline derivatives of the formula: ##STR1## wherein R stands for C.sub.2 H.sub.5, C.sub.2 H.sub.4 F, CH.sub.2 --O--CH.sub.2 --CH.sub.2 OH, ##STR2## to a process for their preparation comprising reacting, for 12-24 hours, at 70.degree.-95.degree. C., in dimethylformamide, the 1,4-dihydro- 3-ethoxycarbonyl- 6,8- difluoro-4-oxo-quinoline with an excess of RX (2-5 mol of RX for one mol of quinoline), in the presence of K.sub.2 CO.sub.3 and subsequently hydrolyzing the obtained 3-ester by HCl under reflux conditions and to pharmaceutical compositions comprising at least one 1,4-dihydro- 3-carboxy- 6,8-difluoro- 1-R-4-oxo-quinoline derivative in admixture with a pharmaceutically acceptable diluent or carrier.

Abstract: This invention relates to 1,3-dihydro-6-methyl-7-hydroxy-furo-(3,4-c)-pyridine derivatives of the general formula I ##STR1## wherein each of A.sub.1 and A.sub.2 independently represents various hydrocarbon groups and therapeutically acceptable addition salts thereof; to a process for the preparation of the same comprising oxidizing the secondary alcohol .alpha..sup.4, 3-o-isopropylidene-1-methyl-5-(1-hydroxy-1-A.sub.1)-methyl pyridine by any usual technique, reacting the resultant ketone with a compound of the general formula XA.sub.2 wherein X stands for Br or I in the presence of magnesium in diethyl ether at the boil and treating the resultant tertiary alcohol with an acidic agent to provoke breaking of the isopropylidene ring and 3,4-cyclisation; and to pharmaceutical compositions containing these derivatives useful for example in diuresis.

Abstract: The present invention relates to the treatment of PAF Acether-induced maladies. The treatment comprises the administration of a ginkgolide or a ginkgolide derivative. Ginkgolide B has been found to be the most effective. The ginkgolides may be introduced orally, intraveneously or by spray inhalation.

Abstract: This invention relates to bornane derivatives of the formula: ##STR1## wherein Z stands for: ##STR2## and Y stands for an arabinose, xylose or ribose rest, the acetylated form of the same, with either a pyrane or furane configuration and bound to the R rest to lead either to the .alpha. or to the .beta. anomer, to a process for the preparation of these compounds and to therapeutic compositions comprising one of them as an essential ingredient.

Abstract: This invention relates to new pyranoderivatives of the formula: ##STR1## wherein X.sub.1 is H, Cl or Br and Z stands for: ##STR2## wherein X.sub.2 is H, Cl or Br, T is O or S and Y stands for an arabinose, xylose or ribose moiety, the acetylated form of the same, with either a pyranose or furanose configuration and bound to the R moiety of either the .alpha. or the .beta. anomer, to a preparation process of said compounds from stoichiometric proportions of the compound R--H and of the selected ose, and to therapeutic compositions, the active ingredient of which comprises at least one of these compounds associated with an appropriate diluent or carrier.

Abstract: This invention relates to therapeutic compositions containing betaine salts for the treatment of hangover and for the lowering of alcohol content in blood in human. Daily dose comprises oral administration of 1 to 30 g, associated with appropriate carrier. Optional ingredients are an analgesic, a buffering agent and caffeine.

Abstract: This invention relates to bicyclic catechol derivatives having the general formulae I and II ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and Z represent various substituents, to a preparation process of the same comprising reacting a compound of formula III ##STR2## wherein R.sub.1 and R.sub.2 have the meanings given above with an appropriately substituted propionic or butyric acid (or an ester or a salt of the same) of formula IV ##STR3## wherein R.sub.3 has the meaning given above, and to therapeutical compositions wherein the active ingredient is one of these compounds.

Abstract: This invention relates to new derivatives of 5-(.omega.-phenethylamino-alkyl) -4,5,6,7-tetrahydro-thieno-(3,2-c)-pyridine of the formula ##STR1## wherein n is an integer of from 2 to 5, R.sub.1 represents a hydrogen atom or a 3,4-dimethoxyphenyl group, R.sub.2 represents a hydrogen atom, an alkyl group having up to 4 carbon atoms or a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group and R.sub.3 represents two or three methoxy groups, to therapeutically acceptable salts thereof, to a process for the preparation of these derivatives comprising condensing a 5-(.omega.-chloroalkyl)-4,5,6,7- tetrahydro- thieno- (3,2-c)-pyridine with the appropriate phenethyl derivative at from 90.degree. to 130.degree. C. under nitrogen circulation and to therapeutic compositions containing said compounds.

Abstract: This invention relates to new 1,3-dihydro-6-[1-cyano-1-isopropyl-N-phenethyl-N-methyl-.omega.-aminoalkyl ]-7-hydroxy-furo-(3,4-c)-pyridine derivatives of the general formula ##STR1## wherein each of A.sub.1 and A.sub.2 independently represents various substituents and to pharmaceutically acceptable salts of said derivatives, to a process for the preparation of the same, comprising reacting, in stoichiometric proportions, at 15.degree.-65.degree. C., in dimethylsulphoxide, a 6-(1-cyano-2-methyl-propyl)-7-hydroxy-furo-(3,4-c)-pyridine derivative with the appropriate N-methyl-N-phenethyl-.omega.-aminoalkyl choride and, finally, to a therapeutic composition of matter comprising as an essential ingredient therein any of said compounds in an amount effective to act as a calcium antagonist or a serotonin antagonist together with an appropriate diluent or carrier.

Abstract: The invention relates to new 5-(1-cyano-1-alkyl-N-methyl-N-methoxy-phenethyl)-alkylamino-2,2,8-trimethy l-4H-dioxino-(4,5-c)-pyridine derivatives of the formula ##STR1## and therapeutically acceptable salts of these compounds, to a preparation process of the same comprising reacting, in stoichiometric proportions, the corresponding 5-(1-cyano-1-R.sub.1)-methyl-2,2,8-trimethyl-4H-dioxino-(4,5-c)-pyridine of the formula ##STR2## on the appropriate [N-methyl-N-(methoxy-phenethyl)]-.omega.-alkyl chloride of the formula ##STR3## The invention relates also to therapeutic compositions containing said derivatives as active ingredients.

Abstract: This invention relates to 1,3 - dihydro-6-aminomethyl-7-hydroxy-furo-(3,4-c)- pyridine derivatives of the general formula I ##STR1## wherein A.sub.1, A.sub.2, R.sub.1 and R.sub.2 represent various substituents, to pharmaceutically acceptable salts of such compounds, to a process for the preparation of compounds comprising reacting a 6-chloromethyl-7-benzoxy derivative of the general formula II ##STR2## with an excess of an amine derivative ##STR3## in a non-polar solvent, at a temperature not exceeding 20.degree. C., which leads to the desired substitution in position 6, followed by an acidic treatment to cleave the benzyl group and, finally to an anti-allergic composition of matter comprising, as an essential ingredient therein, an effective amount of one of these compounds together with an appropriate diluent or carrier.

Abstract: This invention relates to therapeutic compositions containing betaine salts for the treatment of hangover and for the lowering of alcohol content in blood in human. Daily dose comprises oral administration of 1 to 30 g, associated with appropriate carrier. Optional ingredients are an analgesic, a buffering agent and caffeine.

Abstract: The invention relates to new 1,3-dihydro-4-chloro-6-methyl-7-hydroxy-furo-(3,4-c)-pyridine derivatives of the formula ##STR1## to a preparation process of the same from the corresponding non 4-substituted derivatives and to pharmaceutical compositions useful in selective diuresis and lowering of blood pressure wherein said derivatives are the active ingredients.

Abstract: This invention relates to 1,3-dihydro-6-methyl-7-hydroxy-furo-(3,4-c)-pyridine derivatives of the general formula I ##STR1## wherein each of A.sub.1 and A.sub.2 independently represents various hydrocarbon groups and therapeutically acceptable addition salts thereof; to a process for the preparation of the same comprising oxidizing the secondary alchol .alpha..sup.4, 3-o-isopropylidene-1-methyl-5-(1-hydroxy-1-A.sub.1)-methyl pyridine by any usual technique, reacting the resultant ketone with a compound of the general formula XA.sub.2 wherein X stands for Br or I in the presence of magnesium in diethyl ether at the boil and treating the resultant tertiary alcohol with an acidic agent to provoke breaking of the isopropylidene ring and 3,4-cyclization; and to pharmaceutical compositions containing these derivatives.

Abstract: This invention relates to new 1,3-dihydro-6-(1-hydroxy-2-dimethylaminomethyl-allyl)-7-hydroxy-furo-(3,4- c)-pyridine derivatives of the general formula: ##STR1## wherein, each of A.sub.1 and A.sub.2 independently, represents various substituents, to a process for the preparation of these compounds comprising reacting a 6-formyl-7-benzyloxy-furo-(3,4-c)-pyridine derivative of the general formula II ##STR2## with 1-dimethylaminomethyl-vinylmagnesium bromide at the boil, in a non polar solvent and hydrolyzing the 7-benzyloxy group and to a therapeutic composition of matter, comprising as an essential ingredient therein, at least one of these compounds. The compounds according to the invention are of interest for their therapeutic activity, principally as anti-depressive agents.